Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-29 cancelled

30 (Currently Amended). A method for treating a disease, disorder or injury in an organ which is susceptible to a T-cell-mediated specific autoimmune disease, wherein said ~~organ~~ disease, disorder or injury is other than an autoimmune disease, the method comprising immunizing an individual having such a disease, disorder or injury with an agent selected from the group consisting of:

(a) a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of said organ;

(b) a peptide, ~~which~~ the sequence of which is comprised within the sequence of said pathogenic self-antigen of (a);

(c) a peptide obtained by modification of the peptide of (b), which modification consists in the replacement of one or more amino acid residues of the peptide by different amino acid residues, said modified peptide still being capable of recognizing the T-cell receptor recognized by the parent peptide but with less affinity (hereinafter "modified peptide");

(d) a nucleotide sequence encoding a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c) ; and

(e) T cells activated by a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c).

31 (Currently Amended). The method of claim 30, wherein said disease, disorder or injury is a non-autoimmune disease, disorder or injury of the eye and said pathogenic self-antigen is associated with a T-cell-mediated eye-specific autoimmune disease.

32 (Currently Amended). The method of claim 31, wherein said pathogenic self-antigen is an uveitogenic antigen associated with autoimmune uveitis.

33 (Currently Amended). The method of claim 32, wherein said pathogenic uveitogenic antigen is selected from the group consisting of interphotoreceptor retinoid-binding protein (IRBP), S-antigen (S-Ag) and rhodopsin.

34 (Withdrawn/Currently Amended). The method of claim 33, wherein said pathogenic uveitogenic antigen is IRBP and said agent is selected from the group consisting of:

(a) ~~interphotoreceptor retinoid-binding protein (IRBP)~~IRBP;

(b) a peptide, ~~which~~ the sequence of which is comprised within the sequence of IRBP;

(c) a peptide obtained by modification of the peptide of (b), which modification consists in the replacement of one or more amino acid residues of the peptide by different amino acid residues, said modified peptide still being capable of recognizing the T-cell receptor recognized by the parent peptide but with less affinity (hereinafter "modified peptide");

(d) a nucleotide sequence encoding IRPB, a peptide of (b), or a modified peptide of (c); and

(e) T cells activated by an agent selected from the group consisting of IRPB, a peptide of (b), and a modified peptide of (c).

35 (Withdrawn/Currently Amended). The method of claim 34, wherein said agent is a peptide (b), ~~which~~ the sequence of which is comprised within the sequence of IRBP, wherein said agent is selected from the group consisting of the peptides:

ADGSSWEGVGVVPDV (SEQ ID NO:1);

PTARSVGAADGSSWEGVGVVPDV (SEQ ID NO:2); and

HVDDTDLYLTIPTARSVGAADGS (SEQ ID NO:3).

36 (Currently Amended). The method of claim 33, wherein said pathogenic uveitogenic antigen is S-Ag~~S-Antigen~~ and said agent is selected from the group consisting of:

(a) S-Ag~~S-antigen (S-Ag)~~;

(b) a peptide, ~~which~~ the sequence of which is comprised within the sequence of S-Ag;

(c) a peptide obtained by modification of the peptide of (b), which modification consists in the replacement of one or more amino acid residues of the peptide by different amino acid residues, said modified peptide still being capable of recognizing the T-cell receptor recognized by the parent peptide but with less affinity (hereinafter "modified peptide");

(d) a nucleotide sequence encoding S-Ag, a peptide of (b), or a modified peptide of (c) ; and

(e) T cells activated by an agent selected from the group consisting of S-Ag, a peptide of (b), and a modified peptide of (c).

37 (Withdrawn/Currently Amended). The method of claim 36, wherein said agent is a peptide (b), ~~which~~ the sequence of which is comprised within the sequence of S-Ag, wherein said agent is selected from the group consisting of the peptides:

TSSEVATE (SEQ ID NO:4);

DTNLASST (SEQ ID NO:6);

DTNLASSTIIKEGIDKTV (SEQ ID NO:8);

VPLLANNRERRGIALDGKIKHE (SEQ ID NO:9);

TSSEVATEVPFRLMHPQPED (SEQ ID NO:10);

SLTKTLTLVPLLANNRERRG (SEQ ID NO:11);

SLTRTLTLLPLLANNRERAG (SEQ ID NO:12);

KEGIDKTVMGILVSYQIKVKL (SEQ ID NO:13); and

KEGIDRTVLGILVSYQIKVKL (SEQ ID NO:14).

38 (Currently Amended). The method of claim 36, wherein said agent is a modified peptide (c) ~~is~~ selected from the group consisting of the peptides:

TSSEAATE (SEQ ID NO:5); and

DTALASST (SEQ ID NO:7).

39 (Previously Presented). The method of claim 31 for treating a disease, disorder or injury in the eye, wherein said eye disease, disorder or injury is other than an autoimmune disease.

40 (Withdrawn/Currently Amended). The method of claim 39, wherein said non-autoimmune eye disease, disorder or injury is blunt trauma caused by an ~~agent~~ agency selected from the group consisting of a foreign ~~bodies~~body, contusion, laceration, ~~burns~~ burn or laser surgery.

41 (Withdrawn/Currently Amended). The method of claim 39, wherein said non-autoimmune eye disease, disorder or

injury is selected from the group consisting of a conjunctival, a corneal, a retinal, and an optic nerve or optic pathway disorder.

42 (Currently Amended). The method of claim 39, wherein said non-autoimmune eye disease, disorder or injury is glaucoma.